Lowering Costs by Improving Biosimilar Uptake Act

Bill: 117-hr-7047
Sponsor: full_name: Rep. Schrader, Kurt [D-OR-5]
Introduced: 2022-03-09
Policy area: Health
Latest action: action_date: 2022-03-10
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2022-03-09
action_desc: Introduced in House
text: <p><b>Lowering Costs by Improving Biosimilar Uptake Act</b></p> <p>This bill allows for the omission of certain information relating to the strength of a product in a biosimilar application, as determined by the Food and Drug Administration.</p>

tv_txt: I 117th CONGRESS 2d Session H. R. 7047 IN THE HOUSE OF REPRESENTATIVES March 9, 2022 Mr. Schrader introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend title III of the Public Health Service Act with respect to the determination by the Secretary regarding certain biosimilar application elements, and for other purposes.

1. Short title This Act may be cited as the Lowering Costs by Improving Biosimilar Uptake Act . 2. Determination by Secretary regarding certain biosimilar application elements Section 351(k)(2)(A)(ii) of the Public Health Service Act (262(k)(2)(A)(ii)) is amended to read as follows: (ii) Determination by secretary regarding certain application elements (I) In general The Secretary may determine, in the Secretary’s discretion, that an element described in clause (i)(I), or in clause (i)(IV) with respect to the strength of a biological product, is unnecessary in an application submitted under this subsection. (II) Use of determination If the Secretary makes a determination under this clause that information demonstrating that the strength of the biological product is the same as that of the reference product as described in clause (i)(IV) is unnecessary, the term reference product shall, for purposes of this section with respect to such biological product, include all applicable strengths of the reference product. .